Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE

A legfontosabb adatok

Ki végzi
Brixton Biosciences, Inc.
Hol
Boston, Chicago, Edmond, Flint, Gainesville, Houston, Johns Creek, Larkspur, New Orleans, North Bethesda, San Antonio, Sewickley, Tulsa, Washington D.C. és Wichita (Egyesült Államok)Mind a 15 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
263 fő, tervezett
Kezdés
2024. nov. 19.
Várható befejezés
2027. febr. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Neural Ice
  • Triamcinolone acetate
A regiszteradat frissítve
2025. október 28.

Ki vehet részt

Életkor
22 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 22 to 80, inclusive of any gender
  • Baseline pain intensity of >/= 5 of the Numeric Rating Scale (NRS) despite current treatment Confidential Brixton Biosciences Inc. Page 12 of 53 Version: 1.1, 30 August 2024
  • Chronic symptomatic osteoarthritis of the knee (K-L stage 2, 3, or 4) on plain x-rays obtained within the previous 12 months
  • At least 3 months of previous conservative treatments (NSAID, acetaminophen, physical therapy, cortisone injections) that are not currently providing relief
  • Agree to see one doctor (study investigator) for knee pain during the study period
  • Willing/able to understand the informed consent form and provide written informed consent
  • Able to complete outcome measures (including electronic patient reported outcome measures)

Ki nem vehet részt

  • Currently taking >60 MME/day, as determined per MDcalc.com (opioid conversion calculator)
  • Any condition or circumstance that would impact or confound assessment of safety and/or pain. For example, comorbid or concomitant pain conditions, pre-existing lower limb neurologic deficits, any psychiatric or neurologic disease
  • Participation in any clinical study of a therapeutic investigational product within 30 days prior to enrollment
  • Known allergy to glycerol, hyaluronic acid, poloxamer 407, or phosphate buffered saline
  • History of cryoglobulinemia
  • History of cold-induced auto-immune hemolytic anemia (e.g. paroxysmal cold hemoglobinuria or cold agglutinin disease)
  • History of cold urticaria
  • History of Chilblain's (pernio) disease in the lower extremities
  • History of Raynaud's disease
  • Open and/or infected wounds or active tumor at or near the treatment site
  • History of vascular surgery involving femoral vessels on the injection side
  • History of surgical procedures to affected limb that, in the opinion of the investigator, could have impacted the integrity of the genicular nerves or blood vessels
  • Active bacterial or fungal infection that at the discretion of the investigator would preclude study participation
  • History of History of systemic inflammatory conditions such as rheumatoid arthritis
  • Bleeding disorders anticoagulant therapy, unless appropriately stopped or reversed for the procedure
  • Any condition (such as history of significant cardiovascular, renal failure/dialysis, hepatic or other systemic comorbidity/chronic pain condition) or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of study data
  • Use of intra-articular injection of corticosteroid within the previous 3 months, or hyaluronic acid, prolotherapy, Confidential Brixton Biosciences Inc. Page 13 of 53 Version: 1.1, 30 August 2024 autologous blood, or platelet rich plasma injections for the index knee within the previous 6 months
  • Cryoneurolysis, thermal or pulsed radiofrequency ablation, or phenol injection for the index knee within the past 12 months
  • Known contraindication to use of a regional anesthetic block
  • Pregnant, nursing or intent of becoming pregnant during the study period
  • Body habitus/knee anatomy that would preclude the use of the product injection needle size
  • Unwilling to refrain from participation in any other clinical study through the duration of this study
  • Unwilling to refrain from any scheduled surgeries during the duration of this study

Helyszínek itt: Egyesült Államok

  • Brigham and Women's HospitalBoston, Egyesült Államok
  • Insight Hospital and Medical Center ChicagoChicago, Egyesült Államok
  • Clinical Investigations, LLCEdmond, Egyesült Államok
  • Insight Research InstituteFlint, Egyesült Államok
  • The Orthopaedic InstituteGainesville, Egyesült Államok
  • NextStage Clinical Research All-American Orthopedic & Sports Medicine InstituteHouston, Egyesült Államok
  • Emory UniversityJohns Creek, Egyesült Államok
  • Marin HealthLarkspur, Egyesült Államok
  • Ochsner Health SystemNew Orleans, Egyesült Államok
  • NextStage Clinical Research Regenerative Orthopedics and Sports MedicineNorth Bethesda, Egyesült Államok
  • UT San AntonioSan Antonio, Egyesült Államok
  • Pain Diagnostics and Interventional CareSewickley, Egyesült Államok
  • NextStage Clinical Research The Orthopedic CenterTulsa, Egyesült Államok
  • Centers for Advanced OrthopedicsWashington D.C., Egyesült Államok
  • NextStage Clinical Research Advanced Orthopaedic AssociatesWichita, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to evaluate the effectiveness of Neural Ice for pain management associated with knee osteoarthritis in adults aged 22-80 years. Participants will attend study visits and complete subject diaries. Participants will be followed for 6 months after study procedure.

A vizsgálat 2 csoportja

  • Neural Ice injectionsA vizsgált kezelés

    This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.

    Kezelés: Neural Ice

  • Corticosteroid injectionMár használt kezelés, összehasonlításként

    Intraarticular corticosteroid injection is defined as a single dose of Triamcinolone 40mg injected directly into the joint space.

    Kezelés: Triamcinolone acetate

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE: A MULTI-CENTER, RANDOMIZED, CONTROLLED STUDY (ICE STUDY)
A regiszteradat frissítve
2025. október 28.